We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+12.72%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$31.4B
AUM Growth
+$2.72B
(+9.5%)
Cap. Flow
+$31.8M
Cap. Flow
% of AUM
0.1%
Top 10 Holdings %
Top 10 Hldgs %
39.84%
Holding
1,057
New
52
Increased
555
Reduced
391
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SSR Mining
SSRM
|
+$217M |
| 2 |
Kinross Gold
KGC
|
+$120M |
| 3 |
B2Gold
BTG
|
+$94.6M |
| 4 |
Gold Fields
GFI
|
+$80.9M |
| 5 |
Applied Materials
AMAT
|
+$76.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sibanye-Stillwater
SBSW
|
+$275M |
| 2 |
Newmont
NEM
|
+$224M |
| 3 |
B
Barrick Mining
B
|
+$221M |
| 4 |
Franco-Nevada
FNV
|
+$129M |
| 5 |
Wheaton Precious Metals
WPM
|
+$91.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 59.5% |
| 2 | Technology | 13.57% |
| 3 | Healthcare | 5.48% |
| 4 | Financials | 3.32% |
| 5 | Consumer Discretionary | 2.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Prospect Capital
PSEC
$1.09B
| $10.8M | 0.03% |
2,150,109
+216,579
| +11% | +$1.09M |
|
252
Teva Pharmaceuticals
TEVA
$40.5B
| $10.8M | 0.03% |
1,197,285
+316,201
| +36% | +$3.35M |
|
253
FS KKR Capital
FSK
$3.09B
| $10.7M | 0.03% |
673,754
+16,630
| +3% | +$259K |
|
|
BSX.PRA
254
DELISTED
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
| $10.6M | 0.03% |
+95,036
| New | +$10.7M |
|
255
Takeda Pharmaceutical
TAK
$53.4B
| $10.5M | 0.03% |
588,698
+27,839
| +5% | +$507K |
|
256
Main Street Capital
MAIN
$5.22B
| $10.5M | 0.03% |
354,932
+10,420
| +3% | +$319K |
|
257
Oracle
ORCL
$416B
| $10.4M | 0.03% |
174,851
-25,081
| -13% | -$1.42M |
|
258
Duke Energy
DUK
$96.2B
| $10.3M | 0.03% |
115,862
-1,873
| -2% | -$154K |
|
259
NextEra Energy
NEE
$179B
| $10.2M | 0.03% |
147,204
-23,612
| -14% | -$1.63M |
|
260
VEON
VEON
$3.78B
| $10.2M | 0.03% |
323,360
+24,111
| +8% | +$928K |
|
261
JD.com
JD
$43.9B
| $10.2M | 0.03% |
130,846
+44,851
| +52% | +$3.12M |
|
262
GSK
GSK
$103B
| $10.1M | 0.03% |
213,975
-8,552
| -4% | -$428K |
|
263
The Mosaic Company
MOS
$7.44B
| $10.1M | 0.03% |
550,128
+10,019
| +2% | +$163K |
|
264
Honeywell
HON
$78.6B
| $10M | 0.03% |
64,532
-1,083
| -2% | -$161K |
|
265
Patterson-UTI
PTEN
$3.62B
| $10M | 0.03% |
3,509,491
-754,065
| -18% | -$2.77M |
|
266
Sixth Street Specialty
TSLX
$1.72B
| $9.84M | 0.03% |
571,762
+57,218
| +11% | +$980K |
|
267
Transocean
RIG
$5.69B
| $9.77M | 0.03% |
12,104,961
+1,414,373
| +13% | +$2.31M |
|
268
American Tower
AMT
$78.3B
| $9.7M | 0.03% |
40,109
-2,952
| -7% | -$748K |
|
269
Rithm Capital
RITM
$5.64B
| $9.61M | 0.03% |
1,208,548
-184,767
| -13% | -$1.42M |
|
270
Intuit
INTU
$89.7B
| $9.59M | 0.03% |
29,389
-4,512
| -13% | -$1.41M |
|
271
CVS Health
CVS
$126B
| $9.43M | 0.03% |
161,529
+23,005
| +17% | +$1.43M |
|
272
Enbridge
ENB
$113B
| $9.32M | 0.03% |
319,067
-16,646
| -5% | -$524K |
|
273
Jazz Pharmaceuticals
JAZZ
$16.4B
| $9.26M | 0.03% |
64,936
+7,446
| +13% | +$923K |
|
274
VanEck Intermediate Muni ETF
ITM
$2.15B
| $9.18M | 0.03% |
179,100
+159,945
| +835% | +$8.24M |
|
275
Nuveen Municipal Credit Income Fund
NZF
$2.42B
| $9.1M | 0.03% |
619,364
+5,074
| +0.8% | +$76.2K |
|
Similar funds
VanEck Associates's Q3 2020 Portfolio in Review
As of Q3 2020, VanEck Associates held 1,057 positions worth $31.4B, up 9.5% from $28.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
VanEck Associates's Q3 2020 filing shows 52 new, 555 increased, 391 reduced and 42 closed positions. Its largest new stake was Corvus Gold Inc. Common Shares: 8,706,556 shares worth $25.6M. The largest sale was Sibanye-Stillwater, an estimated $275M.
By sector, the portfolio is most concentrated in Materials at 59% of assets, up from 59% a quarter earlier, followed by Technology and Healthcare.
- VanEck Associates's largest Q3 2020 buy was Corvus Gold Inc. Common Shares: 8,706,556 shares worth $25.6M.
- VanEck Associates added most to SSR Mining in Q3 2020, an estimated $217M increase.
- VanEck Associates's biggest Q3 2020 reduction was Sibanye-Stillwater, cutting an estimated $275M.
- VanEck Associates fully exited State Street in Q3 2020, selling an estimated $49.6M.
- VanEck Associates's ten largest holdings make up 40% of its $31.4B portfolio in Q3 2020.
- VanEck Associates opened 52 new positions and closed 42 in Q3 2020.
- VanEck Associates's portfolio value rose 9.5% quarter-over-quarter to $31.4B.
Based on VanEck Associates's 13F filing for Q3 2020, filed 12 Nov 2020.